Literature DB >> 18925458

Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings.

Waldemar Hosch1, Arnt V Kristen, Martin Libicher, Thomas J Dengler, Sebastian Aulmann, Tobias Heye, Philip A Schnabel, Peter Schirmacher, Hugo A Katus, Hans-Ulrich Kauczor, Thomas Longerich.   

Abstract

Late enhancement (LE) in cardiac magnetic resonance imaging (MRI) is a characteristic finding in patients with cardiac amyloidosis (CA) but the histomorphological explanation has not been clarified yet. Five patients with CA were evaluated by MRI prior to heart transplantation. This consisted of morphological, volumetric, and functional data, including LE analysis. For LE analysis, left ventricular (LV) short-axis sections from basal, midventricular, and apical positions were divided into 12 segments resulting in a 36-segment model. Each segment was differentiated by subendocardial, midmural, and subepicardial localization. Histological amyloid and collagenous fiber deposition was correlated with LE in corresponding MRI slides. LE was visualized in 103/180 (57.2%) predominantly subendocardial segments. Histological analysis of amyloid deposition was (peri-)vascular (n = 5), diffuse interstitial (n = 3) and/or nodular (n = 4). Extent of fibrosis was moderate to severe. Cytoplasmatic vacuolization and decline of myofibrils was seen in all patients. Fibrosis was significantly associated with LE in subendocardial and midmural localizations (p<0.05), whereas the extent of amyloid deposition was not associated with LE findings in any region. LE seems to be associated with fibrosis due to ischemia of cardiomyocytes by small vessel amyloid deposition rather than with amyloid deposition in CA, suggesting that amyloid deposition might be present prior to LE detection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925458     DOI: 10.1080/13506120802193233

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  16 in total

1.  MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.

Authors:  Minako Takeda; Yasuo Amano; Masaki Tachi; Hitomi Tani; Kyoichi Mizuno; Shinichiro Kumita
Journal:  Jpn J Radiol       Date:  2013-08-31       Impact factor: 2.374

Review 2.  Tissue characterization of the myocardium: state of the art characterization by magnetic resonance and computed tomography imaging.

Authors:  Puskar Pattanayak; David A Bleumke
Journal:  Radiol Clin North Am       Date:  2014-12-18       Impact factor: 2.303

Review 3.  [Amyloidosis of the heart].

Authors:  A V Kristen; C Röcken
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

4.  Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography.

Authors:  Lu Zhang; Xiao Zhou; Jing Wang; Yang Mu; Bohan Liu; Wenqing Lv; Ye Wang; Hongwei Liu; Hongbin Liu; Guang Zhi
Journal:  Int J Cardiovasc Imaging       Date:  2016-11-23       Impact factor: 2.357

5.  Quantification of extracellular matrix expansion by CMR in infiltrative heart disease.

Authors:  François-Pierre Mongeon; Michael Jerosch-Herold; Otávio Rizzi Coelho-Filho; Ron Blankstein; Rodney H Falk; Raymond Y Kwong
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

6.  Myocardial T1 mapping: techniques and potential applications.

Authors:  Jeremy R Burt; Stefan L Zimmerman; Ihab R Kamel; Marc Halushka; David A Bluemke
Journal:  Radiographics       Date:  2014 Mar-Apr       Impact factor: 5.333

7.  Amyloid in endomyocardial biopsies.

Authors:  Barbara Kieninger; Magdalena Eriksson; Reinhard Kandolf; Philipp A Schnabel; Stefan Schönland; Arnt V Kristen; Ute Hegenbart; Peter Lohse; Christoph Röcken
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

8.  Late gadolinium enhancement in cardiac amyloidosis: attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia.

Authors:  Hiromi Hashimura; Hatsue Ishibashi-Ueda; Yumiko Yonemoto; Keiko Ohta-Ogo; Taka-Aki Matsuyama; Yoshihiko Ikeda; Yoshiaki Morita; Naoaki Yamada; Hiroki Yasui; Hiroaki Naito
Journal:  Heart Vessels       Date:  2015-03-21       Impact factor: 2.037

9.  Cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis.

Authors:  Alfonso Campanile; Fabiola B Sozzi; Ciro Canetta; Gian Battista Danzi
Journal:  Exp Clin Cardiol       Date:  2013

Review 10.  [Risk stratification and treatment of cardiac amyloidoses].

Authors:  A V Kristen; S O Schönland; A Remppis; U Hegenbart; P A Schnabel; H A Katus; T J Dengler
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.